GALMED PHARMACEUTICALS RSS Feed | Nachrichten - www.finanzen.net

Galmed Pharmaceuticals öffnete die Bücher zum abgelaufenen Quartal

Thu, 02 Apr 2026 06:35:06 +0200

Galmed Pharmaceuticals hat am 31.03.2026 Zahlen zum jüngsten Quartal vorgelegt, das am 31.12.2025 endete.Der Verlust je Aktie belief sich auf 0,92 USD. Im Vorjahresquartal waren -1,970 USD je Aktie in ...

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Mon, 08 Dec 2025 14:30:00 +0100

Late Breaking Abstract titled "TargetingSCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol ...

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Thu, 04 Dec 2025 14:30:00 +0100

The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada ...

Galmed Issues CEO Letter to Shareholders

Mon, 01 Dec 2025 14:30:00 +0100

TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or ...

Galmed Pharmaceuticals stellte Ergebnisse des abgelaufenen Quartals vor

Fri, 28 Nov 2025 06:35:06 +0100

Galmed Pharmaceuticals hat am 26.11.2025 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 30.09.2025 – vorgestellt.Dabei wurde ein Verlust je Aktie von 0,33 USD ausgewiesen. ...

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Wed, 26 Nov 2025 14:30:00 +0100

TEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or ...

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Tue, 18 Nov 2025 14:30:00 +0100

The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tablets

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Mon, 17 Nov 2025 14:30:00 +0100

The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect of Bayer's top selling cancer drug, ...